The company
Business model
Board of directors
Intellectual property

Business Model 

QuiaPEG’s business strategy is to build a pipeline of drug development projects using its releasable pegylation technology that will be offered for out-licensing to potential development partners. The company will also seek collaboration with other companies interested in employing reversible pegylation in their own drug development projects. Marketing of end products will - at least initially - be undertaken together with partners with established marketing organisations.

QuiaPEG’s technology is applicable to several stages of drug development, e.g.:

  • Enabling drugability of biomolecules with promising biological effects but challenging pharmacological properties
  • Creating improved versions of already approved drugs as biobetters
  • Prodrug development to extend market exclusivity, i.e. life cycle management
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
+46 (0) 70 693 12 53

User terms & privacy policy
Send a message